EUSA Pharma, a specialty pharmaceutical company focused on oncology, pain control and critical care, has appointed Adrian Haigh VP of global marketing. Haigh will also join the company's executive committee. Haigh joins EUSA from Amgen where he led the international oncology franchise and held joint P&L responsibility for sales of $1.5 billion. He previously held senior commercial and marketing positions at SmithKline Beecham, Schering-Plough, Organon and Novo Nordisk, and has headed affiliate companies in a number of European countries.
Medicure, a cardiovascular focused biopharmaceutical company, announced that Brian Best has been named VP, marketing. Best has 16 years of pharmaceutical industry experience including six years with Millennium Pharmaceuticals and Cor Therapeutics where he held senior positions including director of medical affairs and director of marketing, cardiovascular. Most recently, Best held a senior business development position with PDL BioPharma and led the development of its Ularitide Program.
Osprey Pharmaceuticals, a privately held biotechnology company developing first-in-class leukocyte population modulators for serious, chronic diseases, announced the appointment of Jack Anthony to CEO. Dr. Philip Coggins, who previously held the position of CEO will continue as president and assume the new role of chief scientific officer. Anthony will be based in San Francisco, where Osprey has located most administrative functions, while concentrating its laboratory and R&D operations in Montreal, Canada.